{"classes":[{"categories":[{"measurements":[{"comment":"Median for duration of response (DOR) was not calculated. Lower and upper confidence intervals for DOR were not obtained based on the Kaplan-Meier estimates. Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median for duration of response (DOR) was not calculated. Upper confidence interval for DOR were not obtained based on the Kaplan-Meier estimates. Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"3.5","upperLimit":"NA","value":"NA"},{"comment":"Median for duration of response was not calculated. Lower and upper confidence intervals for DOR were not obtained based on the Kaplan-Meier estimates. Insufficient number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Assessed using ACTG criteria. Summarized statistically using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants enrolled into Cohort 4 and participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG000","title":"Kaposi Sarcoma Cohort (Pembrolizumab and cART)"},{"description":"Treatment naïve participants enrolled into Cohort 4 and treatment naïve participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG001","title":"Treatment Naïve Kaposi Sarcoma Cohort (Pembrolizumab and cART)"},{"description":"Previously treated participants enrolled into Cohort 4 and previously treated participants with evaluable HIV associated Kaposi sarcoma enrolled into Cohorts 1-3, who receive pembrolizumab IV over 30 minutes on day 1. Participants continue receiving their recommended combination antiretroviral therapy per established regimen. Cycles repeat every 21 days for up to 2 years or 35 doses in the absence of disease progression or unacceptable toxicity. Participants undergo physical examination and blood sample collection, and may undergo CT or PET/CT. Participants may also undergo biopsies during screening and on study.\n\nAntiretroviral Therapy: Given PO\n\nBiopsy: Undergo biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT or PET/CT\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: Undergo PET/CT","id":"OG002","title":"Previously Treated Kaposi Sarcoma Cohort (Pembrolizumab and cART)"}],"paramType":"MEDIAN","populationDescription":"Analysis is based on all participants who received at least one dose of study drug. Participants without documented progression were censored at the last disease assessment date.","reportingStatus":"POSTED","timeFrame":"Interval between the date of first response (CR/PR) and the date of progression, assessed up to 2 years","title":"Duration of Response (Kaposi Sarcoma Cohort)","type":"SECONDARY","unitOfMeasure":"months"}